期刊
BREAST
卷 24, 期 2, 页码 131-136出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.breast.2014.12.001
关键词
Estrogen receptor; Synchronous breast neoplasms; Metachronous breast neoplasms; Prognosis; Second primary neoplasm; Molecular epidemiology
资金
- American Cancer Society [MRSG-13-063-01]
- National Cancer Institute in National Institutes of Health [P50 CA125183]
- University of Padova, Italy
- NATIONAL CANCER INSTITUTE [P50CA125183] Funding Source: NIH RePORTER
To examine whether discordance in the hormone-receptor status predicts clinical outcomes in patients with bilateral synchronous (SBC) or metachronous breast cancer (MBC), we analyzed data from the Surveillance, Epidemiology, and End Results program (1998-2011) using Cox models. After excluding 10,231 patients with missing data on hormone receptors in at least one tumor, 4403 SBC and 7159 MBC were included in the study. Among SBC cases, patients with estrogen receptor (ER)-discordant tumors had higher mortality risk (multivariable-adjusted hazard ratio [HR] = 1.96, 95% confidence interval [CI] 1.60-2.40) than patients with ER concordant-positive tumors, whereas patients with ER concordant-negative tumors had the highest risk (HR = 2.49, 95% CI 2.03-3.07). Among MBC cases, patients with a positive-to-negative change in ER status (HR = 1.32, 95% CI: 1.08-1.62) or ER concordant-negative tumors (HR = 1.48, 95% CI: 1.19-1.85) had worse survival than patients with ER concordant-positive tumors. In conclusion, discordance in the hormone-receptor status was an independent predictor of survival outcomes. (C) 2014 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据